Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
27.09
+0.01 (0.04%)
At close: Jul 17, 2026, 4:00 PM EDT
27.63
+0.54 (1.99%)
After-hours: Jul 17, 2026, 6:44 PM EDT
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Mineralys Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $49. The average 1-year stock price forecast is 80.88% higher than the current stock price, while the lowest is $30 (+10.74%) and the highest is $56 (+106.72%).
Price Target: $49 (+80.88%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on Jun 4, 2026.
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 9 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $49 → $42 | Buy | Maintains | $49 → $42 | +55.04% | Jun 4, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $44 → $54 | Buy | Reiterates | $44 → $54 | +99.34% | Jun 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $56 | Buy | Reiterates | $56 | +106.72% | Jun 1, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $48 | Buy | Maintains | $48 | +77.19% | May 19, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
121.38M
EPS This Year
-2.24
from -2.29
EPS Next Year
-2.10
from -2.24
EPS and Forward PE are based on non-GAAP adjusted numbers.